XML 54 R29.htm IDEA: XBRL DOCUMENT
v3.25.3

Organization and Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Sep. 30, 2025
Accounting Policies [Abstract] |
Schedule of Company's Current Pipeline | The following table presents the Company’s current pipeline:
Therapeutic Area | Name | Stage | Product Rights
Cardiometabolic | plozasiran | Phase 3 | Arrowhead(1)
| zodasiran | Phase 3 | Arrowhead
| olpasiran | Phase 3 | Amgen
| ARO-PNPLA3 | Phase 1 | Arrowhead
| GSK4532990 | Phase 2b | GSK
| ARO-INHBE | Phase 1/2a | Arrowhead
| ARO-ALK7 | Phase 1/2a | Arrowhead
| ARO-DIMERPA | Phase 1/2a | Arrowhead
Pulmonary | ARO-RAGE | Phase 1/2a | Arrowhead
| SRP-1002 (ARO-MMP7) | Phase 1/2a | Sarepta
Liver | fazirsiran | Phase 3 | Takeda and Arrowhead
| daplusiran/tomligisiran | Phase 2 | GSK
Neuromuscular | SRP-1001 (ARO-DUX4) | Phase 1/2a | Sarepta
| SRP-1003 (ARO-DM1) | Phase 1/2a | Sarepta
| SRP-1004 (ARO-ATXN2) | Phase 1/2a | Sarepta
| ARO-SNCA | Pre-clinical | Novartis
| ARO-MAPT | Phase 1/2a | Arrowhead
Other | ARO-C3 | Phase 1/2a | Arrowhead
| ARO-CFB | Phase 1/2a | Arrowhead
(1) Greater China rights for plozasiran are out-licensed to Sanofi.
Schedule of Useful Lives of Property Plant and Equipment | The estimated useful lives of property, plant and equipment are as follows (in years):
| Estimated Useful Lives
Buildings | 39
Research equipment | 5
Manufacturing equipment | 7 to 10
Furniture | 7
Computers and software | 3 to 5
Leasehold improvements | Shorter of asset life or lease term
The following table summarizes the Company’s major classes of property, plant and equipment:
| September 30,
| 2025 |  | 2024
| (in thousands)
Land | $ | 2,996 |  |  | $ | 2,996 |
Buildings | 251,317 |  |  | 75,988 |
Research equipment | 62,758 |  |  | 65,353 |
Manufacturing equipment | 18,588 |  |  | — |
Furniture | 5,594 |  |  | 5,594 |
Computers and software | 1,064 |  |  | 981 |
Leasehold improvements | 104,425 |  |  | 104,410 |
Construction in progress | 15,942 |  |  | 188,731 |
| 462,684 |  |  | 444,053 |
Less: Accumulated depreciation and amortization | (80,169) |  |  | (58,021) |
Property, plant and equipment, net | $ | 382,515 |  |  | $ | 386,032 |

X
- Definition Schedule of Current Products + References No definition available. + Details
Name: | arwr_ScheduleOfCurrentProductsTableTextBlock
Namespace Prefix: | arwr_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details
Name: | us-gaap_PropertyPlantAndEquipmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration